Edition:
United Kingdom

Trinity Biotech PLC (TRIB.OQ)

TRIB.OQ on NASDAQ Stock Exchange Global Select Market

4.87USD
4:40pm BST
Change (% chg)

$-0.04 (-0.81%)
Prev Close
$4.91
Open
$4.91
Day's High
$4.91
Day's Low
$4.83
Volume
1,890
Avg. Vol
6,373
52-wk High
$6.47
52-wk Low
$4.30

Latest Key Developments (Source: Significant Developments)

Trinity Biotech reports Q3 earnings per share $0.063
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Trinity Biotech PLC :Trinity biotech announces results for Q3, 2017.Q3 earnings per share $0.063.Q3 revenue $25.6 million versus I/B/E/S view $26.1 million.  Full Article

Trinity Biotech announces withdrawal of Troponin FDA 510(k) submission
Tuesday, 4 Oct 2016 

Trinity Biotech Plc : Trinity biotech announces withdrawal of Troponin FDA 510(k) submission . FDA asked trinity to consider withdrawing their submission, due to some concerns they have about submission . To move technology from swedish facility to facility in ireland where it will be incorporated into research and development,manufacturing infrastructure . Moving of technology will result in closure of uppsala facility in sweden, which will result in approximately 40 redundancies . Trinity biotech announces withdrawal of troponin fda 510(k) submission . Held a meeting with fda on thursday 29 september, in order to obtain an update on company's meritas troponin submission . Fda asked trinity to consider withdrawing their submission, due to some concerns they have about submission . Fda's primary concerns relate to device's operating temperature range . "over coming weeks we will engage with fda to gain a better understanding of nature of their concerns" . Fda concerns also relate to troponin-i clinical performance not being consistent with clinical performance data .Will also recognise a non-cash write-off in excess of $50m, representing costs incurred on project, which will be recognised in q4.  Full Article

BRIEF-Trinity Biotech Announces Q1 Earnings Per Share $0.071

* Q1 REVENUE $23.8 MILLION VERSUS $23.5 MILLION Source text for Eikon: Further company coverage: